Mineralocorticoid receptor antagonists
- PMID: 17362671
- DOI: 10.1007/s11906-007-0009-3
Mineralocorticoid receptor antagonists
Abstract
With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of mineralocorticoid receptor antagonists has provided clinicians with an important tool towards complete blockade of the renin-angiotensin-aldosterone axis.
Similar articles
-
Eplerenone: cardiovascular protection.Circulation. 2003 May 20;107(19):2512-8. doi: 10.1161/01.CIR.0000071081.35693.9A. Circulation. 2003. PMID: 12756192 Review.
-
Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.Int J Cardiol. 2015 Dec 1;200:3-7. doi: 10.1016/j.ijcard.2015.02.096. Int J Cardiol. 2015. PMID: 26404746 Review.
-
Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.Expert Opin Pharmacother. 2007 Dec;8(17):3053-9. doi: 10.1517/14656566.8.17.3053. Expert Opin Pharmacother. 2007. PMID: 18001264 Review.
-
Mineralocorticoid receptor blockade in the protection of target organ damage.Cardiovasc Hematol Agents Med Chem. 2006 Jan;4(1):75-91. doi: 10.2174/187152506775268776. Cardiovasc Hematol Agents Med Chem. 2006. PMID: 16529552 Review.
-
Eplerenone for the treatment of cardiovascular disorders.Expert Rev Cardiovasc Ther. 2012 Jul;10(7):831-8. doi: 10.1586/erc.12.64. Expert Rev Cardiovasc Ther. 2012. PMID: 22908915 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources